Research Topics
| Michelle L O'DonoghueSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency departmentJames L Januzzi
Department of Internal Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA
Arch Intern Med 166:315-20. 2006..Amino-terminal pro-brain natriuretic peptide (NT-proBNP) is useful for diagnosis and triage of patients with dyspnea, but its role for predicting outcomes in such patients remains undefined...
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapyMichelle O'Donoghue
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
Eur Heart J 29:984-91. 2008..To investigate the association between neutrophil count, outcomes, and benefit of clopidogrel therapy in ST-elevation myocardial infarction (STEMI)...- An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trialsMichelle L O'Donoghue
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
J Am Coll Cardiol 60:106-11. 2012..The purpose of this study was to conduct a meta-analysis to examine an invasive or conservative strategy in diabetic versus nondiabetic patients... - Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD programMichelle L O'Donoghue
Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
J Thromb Thrombolysis 34:36-43. 2012..Although atopaxar increased the concentration of Lp-PLA(2) and IL-18, the clinical relevance of these findings remains unknown and warrants further investigation and validation... 
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery diseaseMichelle L O'Donoghue
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02215, USA
Clin Chem 57:1311-7. 2011..Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD)...- Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue
Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 123:1843-53. 2011..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS... - Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L O'Donoghue
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Lancet 374:989-97. 2009..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel... - The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing PlaMichelle O'Donoghue
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
J Am Coll Cardiol 54:678-85. 2009..We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor... - Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysisMichelle O'Donoghue
TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, MA 02115, USA
JAMA 300:71-80. 2008..Although an invasive strategy is frequently used in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), data from some trials suggest that this strategy may not benefit women... - Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study)Michelle O'Donoghue
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Am J Cardiol 100:1336-40. 2007..09 to 10.7, p <0.001). In conclusion, NT-pro-BNP testing offers valuable diagnostic and prognostic information in the evaluation of dyspneic patients with DM in the ED, using identical cutpoints as the population as whole... - Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease TrialStephen D Wiviott
Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Circulation 123:1854-63. 2011..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD... - The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) studyAnnabel Chen
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Card Fail 11:S9-14. 2005..NT-proBNP appears superior to BNP for the evaluation of suspected acute CHF in patients with preserved LVEF... - Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapyWillibald Hochholzer
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am Heart J 162:518-26.e5. 2011..The aims of this analysis were to evaluate the impact of smoking on the antiplatelet effect of clopidogrel and prasugrel and to test the potential interaction of smoking with the treatment effect of these drugs... - Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspneaSandy M Green
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Yawkey 5984, 55 Fruit St, Boston, MA 02114, USA
Arch Intern Med 168:741-8. 2008..We hypothesized that diagnostic uncertainty in this setting is associated with adverse outcomes, and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) testing would improve diagnostic accuracy and reduce diagnostic uncertainty... - Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudyDaniel G Krauser
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
J Card Fail 12:452-7. 2006..CONCLUSION: NT-proBNP is useful for the diagnosis and exclusion of acute HF in dyspneic subjects, irrespective of race or gender... - Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudyDaniel G Krauser
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
Am Heart J 149:744-50. 2005..NT-proBNP fell below the diagnostic cutoff for CHF less often than BNP in overweight and obese individuals; however, when used as a diagnostic tool to identify CHF in such patients, both markers may have reduced sensitivity... - Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) StudySaif Anwaruddin
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
J Am Coll Cardiol 47:91-7. 2006..73 m2 (hazard ratio 1.61; 95% confidence interval 1.14 to 2.26; p = 0.006). CONCLUSIONS: The use of NT-proBNP testing is valuable for the evaluation of the dyspneic patient with suspected CHF, irrespective of renal function... - Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort studyJames L Januzzi
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
Crit Care 10:R37. 2006..Amino-terminal pro-brain natriuretic peptide (NT-proBNP) is useful in evaluating heart failure, but its role in evaluating patients with shock in the intensive care unit (ICU) is not clear... - A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure ScoreAaron L Baggish
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Am Heart J 151:48-54. 2006..CONCLUSION: We report a simple and accurate scoring system combining NT-proBNP testing and clinical assessment for the diagnosis or exclusion of acute HF in patients with dyspnea... - NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudyAnnabel A Chen
Division of Cardiology, Cardiac Ultrasound Laboratory, and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, USA
Eur Heart J 27:839-45. 2006..Routine NT-proBNP testing may thus be useful to triage patients to more timely or deferred echocardiographic evaluation... - Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolismStacy E F Melanson
Department of Pathology, Division of Clinical Laboratories, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA
Arch Pathol Lab Med 130:1326-9. 2006..A combination of both markers may offer reassurance for excluding acute pulmonary embolism, and thus avoid redundant, expensive confirmatory tests... - The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) studyJames L Januzzi
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Am J Cardiol 95:948-54. 2005..NT-proBNP measurement is a valuable addition to standard clinical assessment for the identification and exclusion of acute CHF in the emergency department setting... - Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndromeMichelle L O'Donoghue
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
Am Heart J 162:613-619.e1. 2011..Darapladib inhibits Lp-PLA(2) activity in plasma and in arterial plaques and may confer clinical benefit in preventing cardiovascular events... - Response to "Getting the right message"James L Januzzi
Ann Emerg Med 49:381-3; discussion 383; author reply 384. 2007 - Letter regarding article by Brueckmann et al, "prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis"James L Januzzi
Circulation 113:e25; author reply e25. 2006